Last reviewed · How we verify
Mometasone furoate NS
Mometasone furoate is a corticosteroid that reduces inflammation in the nasal passages by suppressing immune responses and decreasing inflammatory mediator release.
Mometasone furoate is a corticosteroid that reduces inflammation in the nasal passages by suppressing immune responses and decreasing inflammatory mediator release. Used for Allergic rhinitis, Nasal polyps, Chronic rhinosinusitis.
At a glance
| Generic name | Mometasone furoate NS |
|---|---|
| Sponsor | Glenmark Specialty S.A. |
| Drug class | Intranasal corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy / Rhinology |
| Phase | Phase 3 |
Mechanism of action
Mometasone furoate binds to glucocorticoid receptors in nasal tissue, inhibiting the production and release of inflammatory cytokines, chemokines, and adhesion molecules. This reduces nasal inflammation, congestion, and mucus production. As a nasal spray (NS) formulation, it delivers the active corticosteroid directly to the site of inflammation with minimal systemic absorption.
Approved indications
- Allergic rhinitis
- Nasal polyps
- Chronic rhinosinusitis
Common side effects
- Headache
- Pharyngitis
- Epistaxis
- Nasal irritation
- Dysgeusia
Key clinical trials
- To Study GSP 301 in Patients With Seasonal Allergic Rhinitis (PHASE2)
- Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR) (PHASE3)
- Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR) (PHASE3)
- Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR) (PHASE3)
- Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR) (PHASE2)
- Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mometasone furoate NS CI brief — competitive landscape report
- Mometasone furoate NS updates RSS · CI watch RSS
- Glenmark Specialty S.A. portfolio CI